Roche got a boost today in its quest to steer a potentially landmark Huntington’s drug through pivotal development. The EMA handed Roche its PRIME designation for RG6042 — once called IONIS-HTTRx when Ionis was doing the work.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,